On October 15, 2026, a new publication involving setmelanotide appeared in The New England Journal of Medicine. The article is titled "Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. Reply." This entry is identified as a reply piece within the journal's correspondence section. Setmelanotide is an approved compound, and this publication adds to the existing body of literature discussing its use in acquired hypothalamic obesity. No specific findings, data, or outcomes were included in the available event information. The publication is indexed under PubMed ID 42874121 for those seeking to locate the original record. As this is a reply format, it may reference an earlier exchange or correspondence published in the same journal. Readers interested in the full context of the discussion are encouraged to consult the original source directly. For more background on setmelanotide, including its approved uses and general profile, readers can refer to the compound overview.
New Publication on Setmelanotide for Hypothalamic Obesity in NEJM
See the full setmelanotide overview
Source: https://pubmed.ncbi.nlm.nih.gov/42874121/